NH SPAC 2 (206640) - Total Assets
Based on the latest financial reports, NH SPAC 2 (206640) holds total assets worth ₩281.63 Billion KRW (≈ $190.86 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
NH SPAC 2 - Total Assets Trend (2015–2025)
This chart illustrates how NH SPAC 2's total assets have evolved over time, based on quarterly financial data. Also see NH SPAC 2 stock valuation for the company's overall valuation and market capitalisation.
NH SPAC 2 - Asset Composition Analysis
Current Asset Composition (December 2025)
NH SPAC 2's total assets of ₩281.63 Billion consist of 43.5% current assets and 56.5% non-current assets. Review 206640 current and long-term liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 6.9% |
| Accounts Receivable | ₩37.24 Billion | 13.2% |
| Inventory | ₩42.11 Billion | 15.0% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩5.75 Billion | 2.0% |
| Goodwill | ₩316.30 Million | 0.1% |
Asset Composition Trend (2015–2025)
This chart illustrates how NH SPAC 2's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See 206640 share price today for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: NH SPAC 2's current assets represent 43.5% of total assets in 2025, a decrease from 62.3% in 2015.
- Cash Position: Cash and equivalents constituted 6.9% of total assets in 2025, down from 22.9% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, an increase from 0.0% in 2015.
- Asset Diversification: The largest asset category is inventory at 15.0% of total assets.
NH SPAC 2 Competitors by Total Assets
Key competitors of NH SPAC 2 based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Medtronic plc
SA:MDTC34
|
Brazil | R$93.03 Billion |
|
Demant A/S
CO:DEMANT
|
Denmark | Dkr39.07 Billion |
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223
|
China | CN¥16.89 Billion |
|
Jafron Biomedical Co Ltd
SHE:300529
|
China | CN¥5.20 Billion |
|
Sinocare Inc
SHE:300298
|
China | CN¥6.25 Billion |
|
Emvision Medical Devices Ltd
AU:EMV
|
Australia | AU$24.94 Million |
|
Theradiag SA
PA:ALTHE
|
France | €11.55 Million |
|
Biosynex
PA:ALBIO
|
France | €149.44 Million |
NH SPAC 2 - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 5.24 | 4.96 | 3.94 |
| Quick Ratio | 3.44 | 3.54 | 3.09 |
| Cash Ratio | 0.00 | 1.75 | 0.00 |
| Working Capital | ₩99.18 Billion | ₩108.44 Billion | ₩93.30 Billion |
NH SPAC 2 - Advanced Valuation Insights
This section examines the relationship between NH SPAC 2's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.07 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 10.6% |
| Total Assets | ₩281.63 Billion |
| Market Capitalization | $136.73 Million USD |
Valuation Analysis
Below Book Valuation: The market values NH SPAC 2's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: NH SPAC 2's assets grew by 10.6% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for NH SPAC 2 (2015–2025)
The table below shows the annual total assets of NH SPAC 2 from 2015 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | ₩281.63 Billion ≈ $190.86 Million |
+10.59% |
| 2024-12-31 | ₩254.67 Billion ≈ $172.59 Million |
+11.75% |
| 2023-12-31 | ₩227.90 Billion ≈ $154.45 Million |
+16.48% |
| 2022-12-31 | ₩195.66 Billion ≈ $132.59 Million |
+1.78% |
| 2021-12-31 | ₩192.24 Billion ≈ $130.28 Million |
+17.60% |
| 2020-12-31 | ₩163.47 Billion ≈ $110.78 Million |
+61.44% |
| 2019-12-31 | ₩101.26 Billion ≈ $68.62 Million |
-2.11% |
| 2018-12-31 | ₩103.44 Billion ≈ $70.10 Million |
-4.37% |
| 2017-12-31 | ₩108.17 Billion ≈ $73.30 Million |
+19.14% |
| 2016-12-31 | ₩90.79 Billion ≈ $61.53 Million |
+26.62% |
| 2015-12-31 | ₩71.71 Billion ≈ $48.59 Million |
-- |
About NH SPAC 2
Boditech Med Inc. offers instruments and diagnostic reagents in South Korea and internationally. The company offers instruments, including ichroma II, diagnostic immuno-analyzer to measure the presence of various biomarkers for cardiac, cancer, hormones, infectious diseases, autoimmune diseases, and metabolic diseases; ichroma III, a high-throughput immuno-analyzer that enables simultaneous testi… Read more